Tumor Biology in Colorectal Cancer

Preoperative NSAID Use and Tumor Biology in Colorectal Cancer

Inflammation plays a central role in colorectal cancer progression, influencing tumor growth, invasion, and metastatic potential. Lönnroth and colleagues investigated whether short-term exposure to low-dose nonsteroidal anti-inflammatory drugs (NSAIDs) before surgery could alter gene expression within colorectal tumors, potentially affecting aggressive cancer behaviors at a molecular level.
In this study, patients with colorectal cancer received a brief course of low-dose NSAID treatment prior to surgical resection, and tumor tissue was compared with tissue from patients who did not receive NSAIDs. The researchers analyzed gene expression related to proliferation, invasion, angiogenesis, and metastasis. This design allowed assessment of whether even short-term anti-inflammatory exposure could influence biologically meaningful tumor pathways.
Tumors from patients who received NSAIDs showed reduced expression of genes associated with invasive behavior and metastatic potential, along with changes in growth-related signaling pathways. These findings suggest that inflammation-modulating therapies may rapidly influence tumor biology, even over a relatively short preoperative period.
Although this was not designed to assess long-term clinical outcomes such as survival or recurrence, the study provides compelling biological evidence that low-dose NSAID exposure can favorably modify gene expression in colorectal cancer. It supports further research into how anti-inflammatory strategies might be integrated safely and strategically alongside standard cancer treatments to potentially reduce tumor aggressiveness.

Reference:

Lönnroth C, Andersson M, Asting AG, Nordgren S, Lundholm K. Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. Int J Oncol. 2014;45(6):2208–2220. doi:10.3892/ijo.2014.2686. PMID: 25340937; PMCID: PMC4215588.